Philippe Brunet de la Grange
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Philippe Brunet de la Grange.
Stem Cells | 2004
Zoran Ivanovic; Francis Hermitte; Philippe Brunet de la Grange; Bernard Dazey; Francis Belloc; Francis Lacombe; Gerard Vezon; Vincent Praloran
In the present work, we tested the hypothesis that liquid cultures (LCs) of cord blood CD34+ cells at an appropriate low O2 concentration could simultaneously allow colony‐forming cell (CFC) expansion and nonobese diabetic/severe combined immunodeficiency mice–repopulating cell (SRC) maintenance. We first found that 3% was the minimal O2 concentration, still allowing the same rate of CFC expansion as at 20% O2. We report here that 7‐day LCs of cord blood CD34+ cells at 3% O2 maintain SRC better than at 20% O2 and allow a similar amplification of CFCs (35‐ to 50‐fold) without modifying the CD34+ cell proliferation. Their phenotypic profile (antigens: HLA‐DR, CD117, CD33, CD13, CD11b, CD14, CD15, and CD38) was not modified, with exception of CD133, whose expression was lower at 3% O2. These results suggest that low O2 concentrations similar to those found in bone marrow participates in the regulation of hematopoiesis by favoring stem cell–renewing divisions. This expansion method that avoids stem cell exhaustion could be of paramount interest in hematopoietic transplantation by allowing the use of small‐size grafts in adults.
Journal of Cellular Biochemistry | 2006
Philippe Brunet de la Grange; Christophe Barthe; Eric Lippert; Francis Hermitte; Francis Belloc; Francis Lacombe; Zoran Ivanovic; Vincent Praloran
CD34 is a cell surface glycoprotein expressed on hematopoietic stem and progenitor cells that disappears with their maturation. This gene is transcribed in two alternatively spliced mRNAs that encode full length and truncated form of CD34 cell surface antigen. Some publications suggested that CD34 full length plays a role in the maintenance of their self renewal capacity. An examination of CD34 regulation by a low O2 concentration that ensures a better maintenance of stem cells may provide important insights into the molecular control of hematopoiesis. Using human cord blood CD34+ cells, we first compared the effect of short term (24 h) culture in hypoxia (1% O2) and normoxia (20% O2) on the expression of full length and truncated form of cd34 transcripts and on the expression of the CD34 antigen. Hypoxia maintained a larger quantity of cd34 full length transcripts and a higher cd34 full length/cd34 truncated form ratio than normoxia. After 72 h of culture at 1% and 20% O2, sorted CD34low sub‐population from 1% O2 primary culture still contained more cd34 full length mRNAs than those from 20% O2, maintained better CD34 antigen expression during secondary culture at 20% O2 and contained more undifferentiated cells. This work provides the first evidence of the regulation of the cd34 gene by hypoxia resulting in a delayed higher and longer antigen expression by cord blood cells. We suggest that this phenomenon is related to the better maintenance of primitive stem cells in hypoxia. J. Cell. Biochem.
PLOS ONE | 2013
Jean Chevaleyre; Pascale Duchez; Laura Pacheco Rodriguez; Marija Vlaski; Arnaud Villacreces; Véronique Conrad-Lapostolle; Vincent Praloran; Zoran Ivanovic; Philippe Brunet de la Grange
Background Xenotransplantation models allowing the identification and quantification of human Hematopoietic stem cells (HSC) in immunodeficient mice remain the only way to appropriately address human HSC function despite the recent progress in phenotypic characterization. However, these in vivo experiments are technically demanding, time consuming and expensive. Indeed, HSCs engraftment in mouse requires pre-conditioning of animals either by irradiation or cytotoxic drugs to allow homing of injected cells in specific stem cell niches and their subsequent expansion and differentiation in bone marrow. Recently, the development of busulfan pre-conditioning of animals improved the flexibility of experimentation in comparison with irradiation. Design and Methods In order to further facilitate the organization of these complex experiments we investigated the effect of extending the period between mice pre-conditioning and cell injection on the engraftment efficiency. In the meantime, we also explored the role of busulfan doses, mouse gender and intravenous injection route (caudal or retro orbital) on engraftment efficiency. Results and Conclusion We showed that a period of up to 7 days did not modify engraftment efficiency of human HSCs in NSG model. Moreover, retro orbital cell injection to female mice pre-conditioned with 2x25 mg/kg of busulfan seems to be the best adapted schema to detect the human HSC in xenotransplantation experiments.
Oncotarget | 2017
Angela Ianniciello; Pierre-Yves Dumas; Claire Drullion; Amelie V. Guitart; Arnaud Villacreces; Yan Peytour; Jean Chevaleyre; Philippe Brunet de la Grange; Isabelle Vigon; Vanessa Desplat; Muriel Priault; Persio Dello Sbarba; Zoran Ivanovic; François-Xavier Mahon; Jean-Max Pasquet
Albeit tyrosine kinase inhibitors anti-Abl used in Chronic Myeloid Leukemia (CML) block the deregulated activity of the Bcr-Abl tyrosine kinase and induce remission in 90% of patients, they do not eradicate immature hematopoietic compartments of leukemic stem cells. To elucidate if autophagy is important for stem cell survival and/or proliferation, we used culture in low oxygen concentration (0.1% O2 for 7 days) followed back by non-restricted O2 supply (normoxic culture) to mimic stem cell proliferation and commitment. Knockdown of Atg7 expression, a key player in autophagy, in K562 cell line inhibited autophagy compared to control cells. Upon 7 days at 0.1% O2 both K562 and K562 shATG7 cells stopped to proliferate and a similar amount of viable cells remained. Back to non-restricted O2 supply K562 cells proliferate whereas K562 shATG7 cells exhibited strong apoptosis. Using immunomagnetic sorted normal and CML CD34+ cells, we inhibited the autophagic process by lentiviral infection expressing shATG7 or using a Vps34 inhibitor. Both, normal and CML CD34+ cells either competent or deficient for autophagy stopped to proliferate in hypoxia. Surprisingly, while normal CD34+ cells proliferate back to non restricted O2 supply, the CML CD34+ cells deficient for autophagy failed to proliferate. All together, these results suggest that autophagy is required for CML CD34+ commitment while it is dispensable for normal CD34 cells.Albeit tyrosine kinase inhibitors anti-Abl used in Chronic Myeloid Leukemia (CML) block the deregulated activity of the Bcr-Abl tyrosine kinase and induce remission in 90% of patients, they do not eradicate immature hematopoietic compartments of leukemic stem cells. To elucidate if autophagy is important for stem cell survival and/or proliferation, we used culture in low oxygen concentration (0.1% O2 for 7 days) followed back by non-restricted O2 supply (normoxic culture) to mimic stem cell proliferation and commitment. Knockdown of Atg7 expression, a key player in autophagy, in K562 cell line inhibited autophagy compared to control cells. Upon 7 days at 0.1% O2 both K562 and K562 shATG7 cells stopped to proliferate and a similar amount of viable cells remained. Back to non-restricted O2 supply K562 cells proliferate whereas K562 shATG7 cells exhibited strong apoptosis. Using immunomagnetic sorted normal and CML CD34+ cells, we inhibited the autophagic process by lentiviral infection expressing shATG7 or using a Vps34 inhibitor. Both, normal and CML CD34+ cells either competent or deficient for autophagy stopped to proliferate in hypoxia. Surprisingly, while normal CD34+ cells proliferate back to non restricted O2 supply, the CML CD34+ cells deficient for autophagy failed to proliferate. All together, these results suggest that autophagy is required for CML CD34+ commitment while it is dispensable for normal CD34 cells.
Journal of Cellular Physiology | 2018
Antonin Bourdieu; Maryse Avalon; Véronique Lapostolle; Sadek Ismail; Margaux Mombled; Christelle Debeissat; Marianne Guérinet; Pascale Duchez; Jean Chevaleyre; Marija Vlaski-Lafarge; Arnaud Villacreces; Vincent Praloran; Zoran Ivanovic; Philippe Brunet de la Grange
Hematopoietic stem cells (HSCs), which are located in the bone marrow, also circulate in cord and peripheral blood. Despite high availability, HSCs from steady state peripheral blood (SSPB) are little known and not used for research or cell therapy. We thus aimed to characterize and select HSCs from SSPB by a direct approach with a view to delineating their main functional and metabolic properties and the mechanisms responsible for their maintenance. We chose to work on Side Population (SP) cells which are highly enriched in HSCs in mouse, human bone marrow, and cord blood. However, no SP cells from SSBP have as yet been characterized. Here we showed that SP cells from SSPB exhibited a higher proliferative capacity and generated more clonogenic progenitors than non‐SP cells in vitro. Furthermore, xenotransplantation studies on immunodeficient mice demonstrated that SP cells are up to 45 times more enriched in cells with engraftment capacity than non‐SP cells. From a cell regulation point of view, we showed that SP activity depended on O2 concentrations close to those found in HSC niches, an effect which is dependent on both hypoxia‐induced factors HIF‐1α and HIF‐2α. Moreover SP cells displayed a reduced mitochondrial mass and, in particular, a lower mitochondrial activity compared to non‐SP cells, while they exhibited a similar level of glucose incorporation. These results provided evidence that SP cells from SSPB displayed properties of very primitive cells and HSC, thus rendering them an interesting model for research and cell therapy.
Stem Cell Research | 2013
Philippe Brunet de la Grange; Marija Vlaski; Pascale Duchez; Jean Chevaleyre; Véronique Lapostolle; Jean-Michel Boiron; Vincent Praloran; Zoran Ivanovic
Transfusion | 2013
Pascale Duchez; Jean Chevaleyre; Philippe Brunet de la Grange; Marija Vlaski; Jean-Michel Boiron; Guy Wouters; Zoran Ivanovic
Transfusion Clinique Et Biologique | 2017
Darija Loncaric; Laura Pacheco Rodriguez; Veronique Labate; Philippe Brunet de la Grange; Cristelle Debeissat; Marija Vlaski Lafrge; Sonja Pavlovic; Zoran Ivanovic
Transfusion Clinique Et Biologique | 2017
Veronique Lapostolle; Pascale Duchez; Laura Pacheco Rodriguez; Jean Chevaleyre; Philippe Brunet de la Grange; Zoran Ivanovic
Transfusion Clinique Et Biologique | 2017
Laura Pacheco Rodriguez; Philippe Brunet de la Grange; Darija Loncaric; Pascale Duchez; Jean Chevaleyre; Zoran Ivanovic